TD Cowen Maintains Hold Rating on Novartis, Sets $180 Price Target
Key Insights
TD Cowen has maintained a Hold rating on Novartis AG (NVS.US) while setting a target price of $180 per share.
The analyst rating reflects a neutral stance on the pharmaceutical company's near-term stock performance.
The target price was initially raised to $180 and subsequently maintained at that level in a follow-up assessment.
TD Cowen has maintained its Hold rating on Novartis AG (NVS.US), with the firm's target price set at $180 per share, according to data compiled by the independent financial analysis platform TipRanks.
The rating reflects a neutral outlook on the Swiss pharmaceutical giant's stock, suggesting that the analyst does not anticipate significant near-term outperformance or underperformance relative to the broader market. The $180 target price was initially raised in an earlier assessment and subsequently reaffirmed in a follow-up note, indicating consistency in the analyst's valuation perspective.
TipRanks, which aggregates and analyzes recommendations from financial analysts, notes that the information is provided for informational purposes only and does not constitute an investment recommendation. The platform evaluates analyst performance based on success rate—defined as the proportion of ratings that generated a positive return in TipRanks' virtual portfolio over the past year—and average return, assigning a star rating from one to five stars accordingly.
Novartis AG, headquartered in Basel, Switzerland, is one of the world's largest pharmaceutical companies, with a diversified portfolio spanning innovative medicines and generics through its Sandoz division. The Hold rating and $180 target price from TD Cowen represent one data point among many in the broader analyst consensus tracking the company's market performance.